What were the key takeaways from Ekso Bionics's earnings call?

What were the key takeaways from Ekso Bionics’s earnings call?

What is Ekso Bionics's latest dividend and current dividend yield?

What guidance did Ekso Bionics's management provide for the next earnings period?

What factors drove the changes in Ekso Bionics's revenue and profit?

What is the revenue and EPS growth rate for Ekso Bionics year over year?

What is the market's earnings forecast for Ekso Bionics next quarter?

What does Ekso Bionics do and what are its main business segments?

- **Q2 Revenue Miss**: $2.1M (-58% YoY) due to $1.4M deferred Enterprise Health sales, partially offset by 50% growth in Personal Health.
- **Gross Margin Pressure**: 40% vs. 53% YoY, driven by fixed costs and lower-margin distribution.
- **AI & Education Push**: Launched eksoUniversity and NVIDIA Connect program to accelerate exoskeleton adoption with AI voice control.
- **Personal Health Momentum**: 25% of 2025 revenue (vs. 10% in 2024), 45 Medicare beneficiaries in pipeline (+200% YoY).
- **Risks**: 10% of Enterprise customers reliant on federal grants; uncertain pipeline conversion rate.

**【CFO Financial Commentary】**
- Q2 2025 revenue: $2.1 million (down 58% YoY), driven by delays in Enterprise Health sales.
- Gross profit: $800,000 (40% margin), vs. $2.6 million (53% margin) in Q2 2024. Margin decline due to fixed costs, lower-margin distribution sales, and shipping expenses.
- Operating expenses: $4.8 million (4% YoY decline), reflecting cost control.
- Net loss: $2.7 million ($1.24 per share), vs. $2.4 million ($1.99 per share) in Q2 2024.
- Cash balance: $5.2 million as of June 30, 2025.

**【CEO Commercial Update】**
- **Enterprise Health**: Q2 revenue shortfall due to $1.4 million deferred sales (1x North American IDN order and 1x international regulatory delay). CEO expects Q3 closure of the $1 million North American order. 10% of Enterprise customers rely on federal grants, which may impact 2025-2026 sales.
- **Personal Health**: Indego Personal sales grew 50% YoY in H1 2025. Pipeline of 45 Medicare beneficiaries (+200% YoY), though not all may convert. New partnerships with NSM (CRT distributor) and Bionic P&O (O&P provider) driving distribution.
- **AI Initiatives**: Joined NVIDIA Connect program to develop AI voice control for exoskeletons. Early proof of concept with Ekso Voice Agent on EksoNR device. Aiming to leverage 350,000 patient sessions and 15M step data points to build proprietary motion AI.
- **Education & Awareness**: Launched eksoUniversity virtual training platform for PTs, with first CEU certification awarded.

**【Q&A Highlights】**
- **Deferred Sales**: $1.4 million in Q2 delays (North American IDN: $1M, international: $0.4M). CEO confident in Q3 closure of North American order.
- **Personal Health Growth**: 25% of total revenue in 2025 vs. 10% in 2024, with potential to overtake Enterprise Health by 2027.
- **Reimbursement Progress**: 1 ALJ appeal remanded and approved in Q2; CMS reaffirming medical necessity for Indego Personal.
- **Pipeline Risk**: 45 Medicare beneficiaries in pipeline, but no guarantee of conversion due to complex claims process.

Ekso Bionics Holdings, Inc. (EKSO) Q2 2025 Earnings Call Transcript

- **Revenue Softness in Enterprise**: Q1 2025 revenue down 10.5% YoY due to IRF capital delays, but cash burn improves 42.9% YoY.
- **Personal Health Momentum**: 35+ Medicare pipeline candidates (37% growth) supported by NSM and Bionic P&O partnerships.
- **Gross Margin Resilience**: 54% margin sustained via supply chain savings, with >60%+ target for scaled Personal Health.
- **Key Risks**: IDN renewals stable, but new installations face federal grant uncertainty; O&P channel claims success rate >90%.


**【CFO Financial Summary】**
- Q1 2025 Revenue: $3.4M (down 10.5% YoY) due to IRF capital budget delays for Enterprise Health products.
- Gross Margin: 54% (up from 52% YoY), driven by supply chain cost savings and reduced service expenses.
- Operating Expenses: $5.3M (flat YoY), with no material changes in R&D, G&A, or sales costs.
- Net Loss: $2.9M (-14.7% YoY), improving from $3.4M in Q1 2024.
- Cash Position: $8.1M (up 24.6% from Q4 2024), with Q1 cash burn of $2M (down 42.9% YoY).

**【CEO Commercial Update】**
- Enterprise Health Softness: Q1 IRF delays impacted Enterprise revenue, though 2025 IDN renewals remain on track.
- Personal Health Growth: 
  - Pipeline Expansion: 35+ Medicare beneficiaries (37% growth since Q4 2024).
  - Channel Expansion: 
    - NSM CRT Distributor (180+ locations, 250K+ annual mobility solutions).
    - Bionic P&O Distributor (12-state network, ABC-accredited).
    - PRIA Healthcare for claims processing optimization.
- 2025 Outlook: 75-80% revenue from Enterprise, with Personal segment growing QoQ.

**【Q&A Highlights】**
1. **Channel Mix**: 
   - 50-50 split expected between CRT and O&P channels for Personal Health.
   - Enterprise Health to remain >75% of total revenue in 2025.
2. **PRIA Effectiveness**: 
   - Claims success rate >90% post-ALJ guidance implementation.
   - Standardized documentation template reduces denial risk.
3. **IDN Budget Risk**: 
   - Federal grant delays could extend IRF capital constraint into 2026.
   - 2025 IDN renewals unaffected, but new installations face uncertainty.
4. **Gross Margin Trajectory**: 
   - 53-55%+ sustained through 2025 via supply chain efficiency.
   - Long-term >60% target with scale in Personal Health.


Ekso Bionics (EKSO)-5 May 25-2025 Q1 Earnings call transcript

- **Revenue Resilience**: Q4 2024 revenue up 5% YoY, despite full-year decline due to delayed orders
- **Margin Improvement**: Gross margin at 53%, up from 49% YoY, driven by cost savings
- **Strategic Expansion**: 25+ Medicare beneficiaries in pipeline for Indego personal, with Pria partnership for claims
- **2025 Growth Drivers**: Multi-unit orders resuming, personal health segment scaling, Europe/APAC steady growth
- **Operational Efficiency**: 17% YoY reduction in operating expenses, cash usage down 20% YoY

**【CFO Financial Summary】**
- **Q4 2024 Revenue**: $5.1 million (5% YoY growth vs. $4.8 million in Q4 2023)
- **Gross Margin**: 53% (up from 49% in Q4 2023), driven by supply chain cost savings and reduced service costs
- **Operating Expenses**: $4.9 million (15% YoY decline), reflecting headcount reductions and lower discretionary costs
- **Net Loss**: $3.4 million (vs. $3.2 million in Q4 2023)
- **Full Year 2024 Revenue**: $17.9 million (down 2% YoY), impacted by delayed orders from large networks and VA pipeline rebuild
- **Cash Usage**: $9.8 million (down 20% YoY)

**【CEO Strategic Updates】**
- **Ekso Indego Personal Expansion**: 
  - Partnered with Pria Healthcare for Medicare claims management
  - Signed exclusive deal with National Seating & Mobility (NSM) to enter CRT market
  - 25+ qualified Medicare beneficiaries in pipeline, with daily new leads
- **2025 Outlook**: 
  - Expect multi-unit orders from large networks resuming procurement cycles
  - Personal health segment to contribute meaningfully alongside enterprise
  - Europe and APAC growth to continue, with France leading European expansion
- **Operational Efficiency**: 
  - Improved gross margins through supply chain and production optimizations
  - Projected gross margin trend upward in 2025

**【Q&A Highlights】**
- **Order Growth**: 2025 multi-unit orders expected to resume from large networks
- **International Markets**: 
  - Europe: 2024 French hospital surge to taper, returning to normal growth
  - APAC: Ongoing growth in EksoNR and Indego therapy, with potential personal device expansion
- **Patient Qualification**: 
  - Prioritize Medicare beneficiaries with spinal cord injuries meeting FDA criteria
  - Long-term focus on private insurance partnerships
- **Distribution Strategy**: 
  - NSM as CRT leader to drive complex rehab tech adoption
  - Piloting with regional DMEs for O&P integration

Ekso Bionics (EKSO)-3 Mar 25-2024 Q4 Earnings call transcript

Ekso Bionics (EKSO)-28 Oct 24-2024 Q3 Earnings call transcript

Ekso Bionics (EKSO)-29 Jul 24-2024 Q2 Earnings call transcript

Ekso Bionics (EKSO)-29 Apr 24-2024 Q1 Earnings call transcript

Ekso Bionics (EKSO)-4 Mar 24-2023 Q4 Earnings call transcript

Ekso Bionics (EKSO)-26 Oct 23-2023 Q3 Earnings call transcript

Ekso Bionics (EKSO)-27 Jul 23-2023 Q2 Earnings call transcript

Ekso Bionics (EKSO)-28 Apr 23-2023 Q1 Earnings call transcript

Ekso Bionics (EKSO)-28 Mar 23-2022 Q4 Earnings call transcript

Ekso Bionics (EKSO)-3 Nov 22-2022 Q3 Earnings call transcript

Ekso Bionics (EKSO)-28 Jul 22-2022 Q2 Earnings call transcript

Ekso Bionics (EKSO)-28 Apr 22-2022 Q1 Earnings call transcript

Ekso Bionics (EKSO)-25 Feb 22-2021 Q4 Earnings call transcript

Ekso Bionics (EKSO)-3 Nov 21-2021 Q3 Earnings call transcript

Ekso Bionics (EKSO)-29 Jul 21-2021 Q2 Earnings call transcript

Ekso Bionics (EKSO)-29 Apr 21-2021 Q1 Earnings call transcript

Ekso Bionics (EKSO)-25 Feb 21-2020 Q4 Earnings call transcript

Ekso Bionics (EKSO)-29 Oct 20-2020 Q3 Earnings call transcript

Ekso Bionics (EKSO)-30 Jul 20-2020 Q2 Earnings call transcript

Ekso Bionics (EKSO)-30 Apr 20-2020 Q1 Earnings call transcript

Ekso Bionics (EKSO)-27 Feb 20-2019 Q4 Earnings call transcript

Ekso Bionics (EKSO)-30 Oct 19-2019 Q3 Earnings call transcript

Ekso Bionics (EKSO)-2 Aug 19-2019 Q2 Earnings call transcript

Ekso Bionics (EKSO)-1 May 19-2019 Q1 Earnings call transcript

Ekso Bionics (EKSO)-28 Feb 19-2018 Q4 Earnings call transcript

Ekso Bionics (EKSO)-7 Nov 18-2018 Q3 Earnings call transcript

Ekso Bionics (EKSO)-7 Aug 18-2018 Q2 Earnings call transcript

Ekso Bionics (EKSO)-7 May 18-2018 Q1 Earnings call transcript

Ekso Bionics (EKSO)-13 Mar 18-2017 Q4 Earnings call transcript

Ekso Bionics (EKSO)-8 Nov 17-2017 Q3 Earnings call transcript

EKSO

EKSO fundamentals

Earnings Call

You can ask Aime